Vmn1r184 inhibitors are a class of chemical compounds designed to selectively interact with the Vmn1r184 receptor, which is part of the vomeronasal receptor family. These receptors are a subset of the G-protein-coupled receptors (GPCRs) involved in the detection of pheromones in certain species, playing a role in communication and social behavior. Vmn1r184 inhibitors are specifically structured to bind with the receptor's active site, preventing its natural ligand from interacting with it. These inhibitors may be designed with high specificity to disrupt the typical activation of Vmn1r184, offering a way to study the molecular signaling pathways involved in pheromone detection and receptor functionality. Inhibition of Vmn1r184 can provide insights into receptor-ligand binding dynamics and the structural components critical for receptor activation.
Vmn1r184 inhibitors vary in their molecular composition, but they commonly share structural motifs that enable strong receptor affinity while maintaining selective inhibition. These inhibitors may feature heterocyclic rings, aromatic groups, and polar functional groups that contribute to their binding efficiency and receptor specificity. Researchers often employ these inhibitors in controlled settings to observe the effects on receptor signaling cascades, receptor expression, and subsequent biological responses. By inhibiting Vmn1r184 activity, scientists can dissect the receptor's role in broader signaling networks and explore its interaction with related molecular targets. The selective nature of these inhibitors makes them useful tools for probing receptor mechanisms and understanding the biophysical properties of Vmn1r184 and its related receptor family.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist, can modulate GPCR signaling potentially affecting Vmn1r184. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, can alter GPCR-mediated processes potentially impacting Vmn1r184. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, can affect GPCR signaling pathways potentially influencing Vmn1r184. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, can affect noradrenergic signaling potentially related to Vmn1r184. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist, can modulate GPCR pathways potentially related to Vmn1r184 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, can affect calcium signaling pathways potentially related to Vmn1r184. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, can affect GPCR-mediated signaling pathways involved with Vmn1r184. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker, can indirectly influence signaling mechanisms relevant to Vmn1r184. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, can affect downstream signaling pathways that could impact Vmn1r184 function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, can influence GPCR-mediated signaling pathways related to Vmn1r184. | ||||||